Methylene Blue for Long COVID Brain Fog: What the Research Actually Shows

Long COVID brain fog and methylene blue's best-known mechanism point at the same target: mitochondria. A growing body of published research links long COVID and ME/CFS brain fog to mitochondrial dysfunction and reduced cellular energy production. Methylene blue, at low doses, is separately one of the most studied compounds for supporting that same pathway. But those two bodies of research have not yet been connected by a real clinical trial in long COVID patients, and it is important to say that plainly rather than round up.

• The mitochondrial link is real research, not marketing. Multiple 2026 papers name mitochondrial dysfunction as a leading driver of long COVID and ME/CFS brain fog.
• Methylene blue's mechanism is separately well documented. At low, hormetic doses it can act as an alternative electron carrier that supports a stressed electron transport chain.
• The two have not been tested together in a real trial. Only one small pilot study, with a conflict of interest and the wrong primary endpoint, and one theoretical paper touch methylene blue and COVID-19 recovery directly. No randomized controlled trial exists.

Important: if you have long COVID, you may already take an SSRI, SNRI, or another serotonergic medication for the anxiety or depression that often accompanies chronic post-viral illness. Methylene blue has a documented interaction with these medications. Review the full adverse medications list before considering it.

Brain fog is one of the most commonly reported and least understood symptoms of long COVID and its close relative, ME/CFS (myalgic encephalomyelitis, also called chronic fatigue syndrome). Researchers have spent the last several years trying to explain why, and a consistent theme keeps surfacing: the mitochondria, the structures inside your cells responsible for producing energy, are not working the way they should.

A 2026 review in Frontiers in Immunology names mitochondrial dysfunction, alongside neuroinflammation and vascular changes, as a proposed driver of long COVID fatigue and cognitive symptoms (PMID 42404887). Separately, a 2026 paper in the Journal of Translational Medicine proposes a unified mechanistic model for ME/CFS and related chronic post-infectious diseases built around mitochondrial and metabolic reprogramming (PMID 42174604). A third 2026 systematic review of biomarkers across post-acute infection syndromes, including long COVID and ME/CFS, identified mitochondrial stress signaling as a shared feature (PMID 42454043).

Methylene blue's best-documented effect on the body has nothing to do with COVID-19. It comes from decades of independent mitochondrial research conducted for entirely different reasons, mostly memory, neuroprotection, and general cellular energy.

At low, hormetic doses, methylene blue can act as an alternative electron carrier inside the mitochondrial electron transport chain, the pathway your cells use to make ATP. Foundational research from Rojas and Gonzalez-Lima describes this as an electron cycling effect that supports antioxidant activity and cellular respiration at low concentrations, while reversing to a pro-oxidant, respiration-inhibiting effect at high concentrations (PMID 22067440). A 2021 study in Antioxidants demonstrated that methylene blue can donate electrons directly to cytochrome c, bridging around Complexes I and III of the electron transport chain and restoring respiration in mitochondria where those complexes were experimentally blocked (PMID 33669457). A 2022 mechanistic review in Biochemistry (Moscow) confirms this alternative-carrier role and adds that methylene blue also inhibits monoamine oxidase, the same mechanism responsible for its interaction with SSRIs and other serotonergic medications, covered later in this article (PMID 36180986).

This is real, replicated laboratory science. It is also, importantly, science about mitochondria in general, done mostly in animal and cell models, not a study of methylene blue in long COVID patients specifically. For the complete breakdown of this mechanism, see How Does Methylene Blue Work? The Mitochondrial Mechanism Explained.

Here is the honest state of the evidence, without rounding up. As of this writing, no randomized controlled trial has tested methylene blue specifically in long COVID or ME/CFS patients for brain fog or fatigue. Two published items touch the topic directly, and both come with real caveats worth knowing.

Put plainly: the idea that methylene blue could help with long COVID brain fog is mechanistically reasonable. It rests on two real, separately well-supported bodies of research, mitochondrial dysfunction in long COVID and ME/CFS, and methylene blue's electron transport chain effects, that line up logically. But reasonable and proven are different things, and no controlled human trial has connected them yet. Anyone considering methylene blue for this purpose should treat it as exploratory, not established, and should do so under the guidance of a healthcare provider familiar with their full medical history.

This warning applies to everyone considering methylene blue, but it is especially relevant if you are exploring it for long COVID. Long COVID and ME/CFS are frequently accompanied by anxiety, depression, and sleep disruption, and SSRIs, SNRIs, and other serotonergic medications are commonly prescribed for those symptoms. Methylene blue inhibits monoamine oxidase, the enzyme responsible for breaking down serotonin. Combined with a serotonergic medication, this can trigger serotonin syndrome, a potentially life-threatening reaction.

Do not take methylene blue if you are currently using:

• SSRIs, SNRIs, or MAOIs (risk of serotonin syndrome)
• Blood pressure medications
• St. John's Wort, 5-HTP, or CoQ10
• Any other serotonergic medication

Not for use by pregnant or nursing women. Individuals with G6PD deficiency should not take methylene blue. This interaction is well documented: case reports and reviews describe serotonin syndrome following methylene blue in patients on serotonergic drugs (PMID 30104021, PMID 29134498), and a mechanistic review establishes methylene blue as a predictable MAO-A inhibitor (PMID 20142303). The FDA issued a drug safety communication on this exact interaction in October 2011.

Review the full adverse medications list and talk to your doctor, especially if you are managing long COVID alongside a mental health prescription, before starting methylene blue in any form.

Every Nutricel product uses USP-grade methylene blue, is manufactured in an NSF-certified cGMP facility in the United States, and is independently tested through Eurofins. If your interest is the general cellular energy mechanism discussed in this article, these two formulas are the most relevant starting points to research and discuss with your doctor.

Blue Boost is Nutricel's core formula, a clean, research-backed capsule built around methylene blue absorption and cellular energy.

Blue Immune combines methylene blue with copper, NAC, grass-fed beef liver, and vitamins A, C, and E for cellular and immune function support.

Neither product is formulated or marketed to treat long COVID, ME/CFS, or any diagnosed condition. Talk to your doctor about whether either fits your situation.

Mitochondrial dysfunction is a genuinely active research area in long COVID and ME/CFS, and methylene blue's role in supporting mitochondrial electron transport is genuinely well documented, but those two facts have not yet been joined by a real clinical trial.

• The mitochondrial-dysfunction hypothesis for long COVID and ME/CFS brain fog is backed by real, recent, peer-reviewed research.
• Methylene blue's low-dose electron transport chain effect is separately backed by well-replicated lab science.
• Direct evidence connecting the two is thin: one small pilot study with a conflict of interest and one theoretical paper, and no completed randomized controlled trial.
• The serotonin syndrome interaction with SSRIs, SNRIs, and MAOIs is real and well documented, and is especially relevant for long COVID patients managing anxiety or depression.

If you are exploring methylene blue for long COVID or brain fog, treat it as an emerging area of interest rather than a proven solution, and make the decision together with a healthcare provider who knows your full medication history.

Mitochondrial Dysfunction in Long COVID and ME/CFS

Methylene Blue Mechanism (Electron Transport Chain)

Methylene Blue and COVID-19 Recovery (Direct Evidence)

Serotonin Syndrome and Drug Interaction Risk

Sam Carlson, Marketing Developer at Nutricel

Sam is a marketing developer at Nutricel who writes the Nutricel Insights series to help our customers understand methylene blue and make informed choices, translating the published research into plain language. Sam is not a medical professional, and these articles are intended as education rather than medical advice. Every figure in this piece is tied to the studies listed in the references above, and you should always speak with your healthcare provider before starting any supplement.